Faculty

Back to Index
Alan S. Wayne, MD
Professor of Pediatrics (Clinical Scholar)
Interim Director of the Norris Comprehensive Cancer Center
Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles
+1 323 361 2121

Overview

Alan S. Wayne, M.D. is the Associate Director for Pediatric Oncology at the USC Norris Comprehensive Cancer Center, Professor of Pediatrics at the Keck School of Medicine of USC, the Director of the Children's Center for Cancer & Blood Diseases at CHLA, the Head of the Division of Hematology, Oncology and Blood & Marrow Transplantation in the Department of Pediatrics, and the Director of the Pediatric Hematology-Oncology Fellowship Training Program. As the head of the division, Dr. Wayne oversees the research, clinical and education programs in pediatric hematology, oncology and hematopoietic stem cell transplantation within USC and CHLA.

His primary research efforts are directed towards the development of new treatment approaches for leukemias and lymphomas, with a primary focus on relapsed/refractory acute lymphoblastic leukemia. He develops and conducts collaborative laboratory, translational, and clinical investigations, including bench-to-bedside development of targeted, immune-based and cellular therapies, investigator-initiated clinical trials and industry-sponsored studies. Dr. Wayne serves as the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, which is a multinational clinical trials group that conducts Phase I and II trials.

Publications

. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia Pediatr Blood Cancer. 2018 May 24; e27265. View in: PubMed

. Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia Toxins (Basel). 2018 May 21; 10(5). View in: PubMed

. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study Leukemia. 2018 Mar 15. View in: PubMed

. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium Blood. 2018 Mar 08; 131(10):1145-1148. View in: PubMed

. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox Proc Natl Acad Sci U S A. 2018 Feb 20; 115(8):E1867-E1875. View in: PubMed

. The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1-Current state of the workforce Pediatr Blood Cancer. 2018 Feb; 65(2). View in: PubMed

. Cells to prevent/treat relapse following allogeneic stem cell transplantation Hematology Am Soc Hematol Educ Program. 2017 Dec 08; 2017(1):708-715. View in: PubMed

. The PI3Kd Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL Cancers (Basel). 2017 Sep 10; 9(9). View in: PubMed

. Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group Pediatr Hematol Oncol. 2017 Sep - Oct; 34(6-7):355-364. View in: PubMed

. Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting Pediatr Hematol Oncol. 2017 Sep - Oct; 34(6-7):349-354. View in: PubMed

. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia Blood. 2017 10 05; 130(14):1620-1627. View in: PubMed

. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells J Extracell Vesicles. 2017; 6(1):1294368. View in: PubMed

. Biological roles and potential applications of immune cell-derived extracellular vesicles J Extracell Vesicles. 2017; 6(1):1400370. View in: PubMed

. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia Pediatr Blood Cancer. 2016 Nov; 63(11):1943-8. View in: PubMed

. Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design Clin Cancer Res. 2016 Oct 01; 22(19):4913-4922. View in: PubMed

. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias Pediatr Blood Cancer. 2016 Jun; 63(6):997-1005. View in: PubMed

. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates Invest New Drugs. 2016 Feb; 34(1):61-5. View in: PubMed

. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse Biol Blood Marrow Transplant. 2016 12; 22(12):2149-2154. View in: PubMed

. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance J Pediatr Hematol Oncol. 2016 07; 38(5):345-9. View in: PubMed

. Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins Mol Cancer Ther. 2016 05; 15(5):1053-62. View in: PubMed

. Improving access to novel agents for childhood leukemia Cancer. 2015 Jun 15; 121(12):1927-36. View in: PubMed

. Characterization of CD22 expression in acute lymphoblastic leukemia Pediatr Blood Cancer. 2015 Jun; 62(6):964-9. View in: PubMed

. Is another antibody conjugate against ALL needed? Lancet Haematol. 2015 Mar; 2(3):e87-8. View in: PubMed

. Abnormal bone marrow histopathology in paediatric mastocytosis Br J Haematol. 2015 Mar; 168(6):865-73. View in: PubMed

. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet. 2015 Feb 07; 385(9967):517-528. View in: PubMed

. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation Blood. 2015 Jan 29; 125(5):784-92. View in: PubMed

. Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant. 2014 Jul; 20(7):1033-9. View in: PubMed

. Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia Biol Blood Marrow Transplant. 2014 Jul; 20(7):1000-7. View in: PubMed

. Immunotoxins for leukemia Blood. 2014 Apr 17; 123(16):2470-7. View in: PubMed

. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part IIIPrevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13. View in: PubMed

. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part IIAutologous Transplantation-novel agents and immunomodulatory strategies. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1661-9. View in: PubMed

. Simplified process for the production of anti-CD19-CAR-engineered T cells Cytotherapy. 2013 Nov; 15(11):1406-15. View in: PubMed

. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction Biol Blood Marrow Transplant. 2013 Nov; 19(11):1534-6. View in: PubMed

. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part IBiology of relapse after transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1537-45. View in: PubMed

. Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8 Leuk Res. 2013 Nov; 37(11):1551-6. View in: PubMed

. A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene J Biol Chem. 2013 Apr 26; 288(17):12305-12. View in: PubMed

. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype Pharmacotherapy. 2013 Mar; 33(3):e19-22. View in: PubMed

. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia Blood. 2013 Feb 14; 121(7):1165-74. View in: PubMed

. Immunotherapy for pediatric leukemia Front Oncol. 2013; 3:166. View in: PubMed

. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia J Clin Oncol. 2012 Nov 01; 30(31):3876-83. View in: PubMed

. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans Blood. 2012 Nov 01; 120(18):3635-46. View in: PubMed

. Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges Am J Hematol. 2012 Sep; 87(9):916-22. View in: PubMed

. Pretransplant MRD: the light is yellow, not red Blood. 2012 Jul 12; 120(2):244-6. View in: PubMed

. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy Proc Natl Acad Sci U S A. 2012 May 01; 109(18):6898-903. View in: PubMed

. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas Biol Blood Marrow Transplant. 2012 May; 18(5):698-707. View in: PubMed

. Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiencyJ Allergy Clin Immunol. 2012 Mar; 129(3):762-769. e1. View in: PubMed

. Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain Blood. 2012 Feb 23; 119(8):1848-55. View in: PubMed

. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations Clin Lymphoma Myeloma Leuk. 2012 Feb; 12(1):20-5. View in: PubMed

. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies PLoS One. 2012; 7(12):e52655. View in: PubMed

. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates Cancer Res. 2011 Oct 15; 71(20):6300-9. View in: PubMed

. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency Blood. 2011 Sep 08; 118(10):2688-94. View in: PubMed

. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States Blood. 2011 Jun 02; 117(22):5835-49. View in: PubMed

. Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737 Leuk Lymphoma. 2011 Jun; 52 Suppl 2:79-81. View in: PubMed

. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54. View in: PubMed

. Variables affecting the quantitation of CD22 in neoplastic B cells Cytometry B Clin Cytom. 2011 Mar; 80(2):83-90. View in: PubMed

. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells J Immunother. 2011 Mar; 34(2):187-95. View in: PubMed

. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503. View in: PubMed

. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications Haematologica. 2010 Nov; 95(11):1873-9. View in: PubMed

. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantationpart II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46. View in: PubMed

. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell TransplantationPart I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211. View in: PubMed

. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia Br J Haematol. 2010 Aug; 150(3):352-8. View in: PubMed

. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Biol Blood Marrow Transplant. 2010 May; 16(5):563-4. View in: PubMed

. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma Blood. 2010 Apr 15; 115(15):3017-24. View in: PubMed

. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial Clin Cancer Res. 2010 Mar 15; 16(6):1894-903. View in: PubMed

. Hematopoietic stem cell transplantation for leukemia Pediatr Clin North Am. 2010 Feb; 57(1):1-25. View in: PubMed

. Immunotherapy of childhood cancer: from biologic understanding to clinical application Curr Opin Pediatr. 2010 Feb; 22(1):2-11. View in: PubMed

. Immune-based therapeutics for pediatric cancer Expert Opin Biol Ther. 2010 Feb; 10(2):163-78. View in: PubMed

. Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia Pediatr Blood Cancer. 2010 Jan; 54(1):173-5. View in: PubMed

. Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease Transfus Apher Sci. 2009 Dec; 41(3):209-16. View in: PubMed

. Application of immunotherapy in pediatric leukemia Curr Hematol Malig Rep. 2009 Jul; 4(3):159-66. View in: PubMed

. Progress in the curative treatment of childhood hematologic malignancies J Natl Cancer Inst. 2008 Sep 17; 100(18):1271-3. View in: PubMed

. Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients J Proteomics. 2008 Apr 30; 71(1):61-70. View in: PubMed

. Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy Pediatr Infect Dis J. 2008 Mar; 27(3):265-8. View in: PubMed

. Sibling stem cell donor experiences at a single institution Psychooncology. 2008 Mar; 17(3):304-7. View in: PubMed

. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation Obstet Gynecol. 2007 Nov; 110(5):1041-9. View in: PubMed

. Thromboembolic events in children and young adults with pediatric sarcoma J Clin Oncol. 2007 Apr 20; 25(12):1519-24. View in: PubMed

. The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions Transfusion. 2007 Mar; 47(3):545-50. View in: PubMed

. Hematopoietic stem cell donation in children: a review of the sibling donor experience J Psychosoc Oncol. 2007; 25(1):45-66. View in: PubMed

. Psychotropic medication use in pediatric patients with cancer Arch Pediatr Adolesc Med. 2006 Aug; 160(8):818-22. View in: PubMed

. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: VAncillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006 Apr; 12(4):375-96. View in: PubMed

. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):22-30. View in: PubMed

. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database J Clin Oncol. 2005 Jul 20; 23(21):4735-41. View in: PubMed

. Two novel CHS1 (LYST) mutations: clinical correlations in an infant with Chediak-Higashi syndrome Mol Genet Metab. 2005 Jun; 85(2):125-32. View in: PubMed

. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis J Clin Oncol. 2004 Sep 15; 22(18):3798-804. View in: PubMed

. Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens Transfusion. 2004 Feb; 44(2):229-38. View in: PubMed

. Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes Hematol Oncol Clin North Am. 2003 Oct; 17(5):1243-60. View in: PubMed

Powered bySC CTSI